CD4 and melanoma: Using a preclinical mouse model of B16-F10 melanoma overexpressing IDO1 (B16IDO), authors demonstrated that IDO-expressing tumors have marked increases in Treg frequency and upregulated expression of FoxP3 in tumor infiltrating CD4+ T cells compared to B16WT-tumor bearing mice.